|
SE430062B
(sv)
|
1977-03-04 |
1983-10-17 |
Pharmacia Fine Chemicals Ab |
Kopplings- eller tioleringsreagens
|
|
US4137230A
(en)
|
1977-11-14 |
1979-01-30 |
Takeda Chemical Industries, Ltd. |
Method for the production of maytansinoids
|
|
US4307016A
(en)
|
1978-03-24 |
1981-12-22 |
Takeda Chemical Industries, Ltd. |
Demethyl maytansinoids
|
|
US4256746A
(en)
|
1978-11-14 |
1981-03-17 |
Takeda Chemical Industries |
Dechloromaytansinoids, their pharmaceutical compositions and method of use
|
|
JPS55102583A
(en)
|
1979-01-31 |
1980-08-05 |
Takeda Chem Ind Ltd |
20-acyloxy-20-demethylmaytansinoid compound
|
|
JPS55162791A
(en)
|
1979-06-05 |
1980-12-18 |
Takeda Chem Ind Ltd |
Antibiotic c-15003pnd and its preparation
|
|
JPS5645483A
(en)
|
1979-09-19 |
1981-04-25 |
Takeda Chem Ind Ltd |
C-15003phm and its preparation
|
|
JPS5645485A
(en)
|
1979-09-21 |
1981-04-25 |
Takeda Chem Ind Ltd |
Production of c-15003pnd
|
|
EP0028683A1
(en)
|
1979-09-21 |
1981-05-20 |
Takeda Chemical Industries, Ltd. |
Antibiotic C-15003 PHO and production thereof
|
|
WO1982001188A1
(en)
|
1980-10-08 |
1982-04-15 |
Takeda Chemical Industries Ltd |
4,5-deoxymaytansinoide compounds and process for preparing same
|
|
US4450254A
(en)
|
1980-11-03 |
1984-05-22 |
Standard Oil Company |
Impact improvement of high nitrile resins
|
|
US4313946A
(en)
|
1981-01-27 |
1982-02-02 |
The United States Of America As Represented By The Secretary Of Agriculture |
Chemotherapeutically active maytansinoids from Trewia nudiflora
|
|
US4315929A
(en)
|
1981-01-27 |
1982-02-16 |
The United States Of America As Represented By The Secretary Of Agriculture |
Method of controlling the European corn borer with trewiasine
|
|
US4563304A
(en)
|
1981-02-27 |
1986-01-07 |
Pharmacia Fine Chemicals Ab |
Pyridine compounds modifying proteins, polypeptides or polysaccharides
|
|
JPS57192389A
(en)
|
1981-05-20 |
1982-11-26 |
Takeda Chem Ind Ltd |
Novel maytansinoid
|
|
US4664911A
(en)
|
1983-06-21 |
1987-05-12 |
Board Of Regents, University Of Texas System |
Immunotoxin conjugates employing toxin B chain moieties
|
|
DE3584012D1
(de)
|
1985-01-22 |
1991-10-10 |
Saint Gobain Vitrage |
Verfahren zur herstellung eines pulvers auf basis von indium-formiat zur herstellung einer duennen beschichtung auf einem substrat, insbesondere auf glas.
|
|
GB8600582D0
(en)
|
1986-01-10 |
1986-02-19 |
Ca Minister Nat Defence |
Purifying biological materials
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US4859449A
(en)
|
1987-09-14 |
1989-08-22 |
Center For Molecular Medicine And Immunology |
Modified antibodies for enhanced hepatocyte clearance
|
|
US5241078A
(en)
|
1988-06-14 |
1993-08-31 |
Cetus Oncology |
Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom
|
|
US5024834A
(en)
|
1988-07-12 |
1991-06-18 |
Cetus Corporation |
Thioether linked immunotoxin conjugates
|
|
CA2006408A1
(en)
|
1988-12-27 |
1990-06-27 |
Susumu Iwasa |
Bispecific monoclonal antibody, its production and use
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5714149A
(en)
|
1989-02-10 |
1998-02-03 |
Celltech Therapeutics Limited |
Crosslinked antibodies and processes for their preparation
|
|
US5208020A
(en)
|
1989-10-25 |
1993-05-04 |
Immunogen Inc. |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
CA2026147C
(en)
|
1989-10-25 |
2006-02-07 |
Ravi J. Chari |
Cytotoxic agents comprising maytansinoids and their therapeutic use
|
|
US6316003B1
(en)
|
1989-12-21 |
2001-11-13 |
Whitehead Institute For Biomedical Research |
Tat-derived transport polypeptides
|
|
US5137877B1
(en)
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
|
ES2108048T3
(es)
|
1990-08-29 |
1997-12-16 |
Genpharm Int |
Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
CA2048078A1
(en)
|
1990-11-15 |
1992-05-16 |
Wolfgang A. Wrasidlo |
Chemical modification of antibodies for creation of immunoconjugates
|
|
US5252714A
(en)
|
1990-11-28 |
1993-10-12 |
The University Of Alabama In Huntsville |
Preparation and use of polyethylene glycol propionaldehyde
|
|
SE9102074D0
(sv)
|
1991-07-03 |
1991-07-03 |
Kabi Pharmacia Ab |
Tomour antigen specific antibody
|
|
SE470006B
(sv)
|
1991-09-26 |
1993-10-25 |
Corline Systems Ab |
Nytt konjugat, dess framställning och användning samt substrat preparerat med konjugatet
|
|
ATE463573T1
(de)
|
1991-12-02 |
2010-04-15 |
Medimmune Ltd |
Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
|
|
DK0563475T3
(da)
|
1992-03-25 |
2000-09-18 |
Immunogen Inc |
Konjugater af cellebindende midler og derivater af CC-1065
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
US5556623A
(en)
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
|
IL111748A0
(en)
|
1993-12-03 |
1995-01-24 |
Zeneca Ltd |
Proteins
|
|
US5747446A
(en)
|
1994-03-22 |
1998-05-05 |
Beth Israel Deaconess Medical Center |
Modified polypeptides with increased biological activity
|
|
US5919758A
(en)
|
1994-03-22 |
1999-07-06 |
Beth Israel Deaconess Medical Center |
Modified polypeptides with altered biological activity
|
|
US5580853A
(en)
|
1994-03-22 |
1996-12-03 |
New England Deaconess Hospital |
Modified polypeptides with increased biological activity
|
|
US5612474A
(en)
|
1994-06-30 |
1997-03-18 |
Eli Lilly And Company |
Acid labile immunoconjugate intermediates
|
|
WO1996039183A1
(en)
|
1995-05-31 |
1996-12-12 |
Fred Hutchinson Cancer Research Center |
Compositions and methods for targeted delivery of effector molecules
|
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
|
US5958872A
(en)
|
1996-04-01 |
1999-09-28 |
Apoptosis Technology, Inc. |
Active survival domains of IGF-IR and methods of use
|
|
WO1998026747A2
(en)
|
1996-12-17 |
1998-06-25 |
Terman David S |
Superantigen based methods and compositions for treatment of diseases
|
|
US6462070B1
(en)
|
1997-03-06 |
2002-10-08 |
The General Hospital Corporation |
Photosensitizer conjugates for pathogen targeting
|
|
US6371975B2
(en)
|
1998-11-06 |
2002-04-16 |
Neomend, Inc. |
Compositions, systems, and methods for creating in situ, chemically cross-linked, mechanical barriers
|
|
ATE282092T1
(de)
|
1997-06-11 |
2004-11-15 |
Borean Pharma As |
Trimerisierendes modul
|
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
|
US5958677A
(en)
*
|
1997-07-28 |
1999-09-28 |
The New York Blood Center, Inc. |
Method for purifying viral nucleic acids
|
|
JP2002501721A
(ja)
|
1997-08-01 |
2002-01-22 |
モルフォシス・アクチェンゲゼルシャフト |
多量体（ポリ）ペプチドコンプレックスのメンバーをコードする核酸配列を同定するための新規方法およびファージ
|
|
US5965714A
(en)
|
1997-10-02 |
1999-10-12 |
Connaught Laboratories, Inc. |
Method for the covalent attachment of polysaccharides to protein molecules
|
|
IL135148A0
(en)
|
1997-10-03 |
2001-05-20 |
Galenica Pharmaceuticals Inc |
A polysaccharide conjugate and pharmaceutical compositions containing the same
|
|
US6121236A
(en)
|
1998-03-24 |
2000-09-19 |
The Children's Medical Center Corporation |
Multivalent ligands which modulate angiogenesis
|
|
EP1073667A2
(en)
|
1998-04-28 |
2001-02-07 |
Galenica Pharmaceuticals, Inc. |
Polysaccharide-antigen conjugates
|
|
US5981564A
(en)
|
1998-07-01 |
1999-11-09 |
Universite Laval |
Water-soluble derivatives of paclitaxel, method for producing same and uses thereof
|
|
EP1098665B9
(en)
|
1998-07-13 |
2003-08-13 |
The Board Of Regents, The University Of Texas System |
Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids
|
|
US6780327B1
(en)
|
1999-02-25 |
2004-08-24 |
Pall Corporation |
Positively charged membrane
|
|
TW593241B
(en)
|
1999-04-20 |
2004-06-21 |
Hoffmann La Roche |
Carbamic acid derivatives
|
|
AUPQ014799A0
(en)
|
1999-05-04 |
1999-05-27 |
Access Pharmaceuticals Australia Pty Limited |
Amplification of folate-mediated targeting to tumor cells using polymers
|
|
HK1049787B
(en)
|
1999-10-01 |
2014-07-25 |
Immunogen, Inc. |
Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
|
|
NZ517772A
(en)
|
1999-11-24 |
2004-03-26 |
Immunogen Inc |
Cytotoxic agents comprising taxanes and their therapeutic use
|
|
EP1242438B1
(en)
|
1999-12-29 |
2006-11-08 |
Immunogen, Inc. |
Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
|
|
US20020197266A1
(en)
|
2000-02-08 |
2002-12-26 |
Waldemar Debinski |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
|
US6632979B2
(en)
|
2000-03-16 |
2003-10-14 |
Genentech, Inc. |
Rodent HER2 tumor model
|
|
US7097840B2
(en)
|
2000-03-16 |
2006-08-29 |
Genentech, Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
|
US6333410B1
(en)
|
2000-08-18 |
2001-12-25 |
Immunogen, Inc. |
Process for the preparation and purification of thiol-containing maytansinoids
|
|
US6596503B1
(en)
|
2000-08-18 |
2003-07-22 |
East Carolina University |
Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
|
|
US20060062786A1
(en)
|
2000-11-08 |
2006-03-23 |
Human Genome Sciences, Inc. |
Antibodies that immunospecifically bind to TRAIL receptors
|
|
EP2796468A2
(en)
|
2001-01-05 |
2014-10-29 |
Pfizer Inc |
Antibodies to insulin-like growth factor I receptor
|
|
EP1373321A2
(en)
|
2001-01-29 |
2004-01-02 |
Idec Pharmaceuticals Corporation |
Modified antibodies and methods of use
|
|
ATE337011T1
(de)
|
2001-02-07 |
2006-09-15 |
Beth Israel Hospital |
Modifizierte psma-liganden und deren verwendung
|
|
EP1389090A2
(en)
|
2001-04-26 |
2004-02-18 |
Board of Regents, The University of Texas System |
Diagnostic imaging compositions, their methods of synthesis and use
|
|
JP2004533449A
(ja)
|
2001-05-11 |
2004-11-04 |
ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム |
Ｃｄ２６を発現している細胞に関連する疾患の治療としての抗ｃｄ２６モノクローナル抗体
|
|
EP1258255A1
(en)
|
2001-05-18 |
2002-11-20 |
Boehringer Ingelheim International GmbH |
Conjugates of an antibody to CD44 and a maytansinoid
|
|
US6441163B1
(en)
|
2001-05-31 |
2002-08-27 |
Immunogen, Inc. |
Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
|
|
ATE535258T1
(de)
|
2001-06-01 |
2011-12-15 |
Cornell Res Foundation Inc |
Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
|
|
US6576802B2
(en)
|
2001-06-04 |
2003-06-10 |
Shell Oil Company |
One-step production of 1, 3-propanediol from ethylene oxide and syngas with a catalyst with a phospholanoalkane ligand
|
|
EP1455817B1
(en)
|
2001-12-11 |
2008-12-31 |
Merck & Co., Inc. |
Staphylococcus aureus exopolysaccharide and process
|
|
US6716821B2
(en)
|
2001-12-21 |
2004-04-06 |
Immunogen Inc. |
Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
|
|
JP2005532258A
(ja)
|
2002-01-03 |
2005-10-27 |
スミスクライン・ビーチャム・コーポレイション |
免疫コンジュゲートの調製方法
|
|
US8877901B2
(en)
|
2002-12-13 |
2014-11-04 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US7591994B2
(en)
|
2002-12-13 |
2009-09-22 |
Immunomedics, Inc. |
Camptothecin-binding moiety conjugates
|
|
US6756397B2
(en)
|
2002-04-05 |
2004-06-29 |
Immunogen, Inc. |
Prodrugs of CC-1065 analogs
|
|
US6534660B1
(en)
|
2002-04-05 |
2003-03-18 |
Immunogen, Inc. |
CC-1065 analog synthesis
|
|
AU2003265235A1
(en)
|
2002-04-26 |
2003-12-19 |
Genetech, Inc. |
Non-affinity purification of proteins
|
|
DK1507556T3
(en)
|
2002-05-02 |
2016-09-12 |
Wyeth Holdings Llc |
Calicheamicin derivative-carrier conjugates
|
|
US20090068178A1
(en)
|
2002-05-08 |
2009-03-12 |
Genentech, Inc. |
Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
|
|
US20050276812A1
(en)
|
2004-06-01 |
2005-12-15 |
Genentech, Inc. |
Antibody-drug conjugates and methods
|
|
US6596757B1
(en)
|
2002-05-14 |
2003-07-22 |
Immunogen Inc. |
Cytotoxic agents comprising polyethylene glycol-containing taxanes and their therapeutic use
|
|
CA2490423A1
(en)
|
2002-06-21 |
2003-12-31 |
Biogen Idec Inc. |
Buffered formulations for concentrating antibodies and methods of use thereof
|
|
US7390898B2
(en)
|
2002-08-02 |
2008-06-24 |
Immunogen Inc. |
Cytotoxic agents containing novel potent taxanes and their therapeutic use
|
|
DE60336149D1
(de)
|
2002-08-16 |
2011-04-07 |
Immunogen Inc |
Vernetzer mit hoher reaktivität und löslichkeit und ihre verwendung bei der herstellung von konjugaten für die gezielte abgabe von kleinmolekularen arzneimitteln
|
|
ES2314238T3
(es)
|
2002-10-08 |
2009-03-16 |
Fresenius Kabi Deutschland Gmbh |
Conjugados de oligosacaridos farmaceuticamente activos.
|
|
PT1558744E
(pt)
|
2002-10-30 |
2011-09-22 |
Nuevolution As |
Codificação enzimática
|
|
DK1578446T3
(en)
|
2002-11-07 |
2015-06-29 |
Immunogen Inc |
ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
|
|
JP4703566B2
(ja)
|
2003-05-14 |
2011-06-15 |
イムノゲン インコーポレーティッド |
薬剤複合体組成物
|
|
US8088387B2
(en)
|
2003-10-10 |
2012-01-03 |
Immunogen Inc. |
Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
|
|
US7276497B2
(en)
|
2003-05-20 |
2007-10-02 |
Immunogen Inc. |
Cytotoxic agents comprising new maytansinoids
|
|
CR20170291A
(es)
|
2003-05-20 |
2017-07-27 |
Immunogen Inc |
Agentes citotoxicos mejorados que comprenden nuevos maitansinóides
|
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
|
US20050074425A1
(en)
|
2003-07-02 |
2005-04-07 |
Polycord, Inc. |
Method for delivering polymerized therapeutic agent compositions and compositions thereof
|
|
CA2542886A1
(en)
|
2003-11-05 |
2005-05-19 |
Neelima M. Bhat |
Enhanced b cell cytotoxicity of cdim binding antibody
|
|
US20050175619A1
(en)
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
|
US20110064754A1
(en)
|
2005-03-03 |
2011-03-17 |
Center For Molecular Medicine And Immunology |
Immunoconjugates Comprising Poxvirus-Derived Peptides and Antibodies Against Antigen-Presenting Cells for Subunit-Based Poxvirus Vaccines
|
|
EP1610818A4
(en)
|
2004-03-03 |
2007-09-19 |
Millennium Pharm Inc |
MODIFIED ANTIBODIES AGAINST A PROSTATE-SPECIFIC MEMBRANE-ANTIGEN AND USE THEREOF
|
|
US8470315B2
(en)
|
2004-04-13 |
2013-06-25 |
Quintessence Biosciences, Inc. |
Non-natural ribonuclease conjugates as cytotoxic agents
|
|
US20060073528A1
(en)
|
2004-05-14 |
2006-04-06 |
Jean-Michel Lecerf |
Measurement methods
|
|
RU2402548C2
(ru)
|
2004-05-19 |
2010-10-27 |
Медарекс, Инк. |
Химические линкеры и их конъюгаты
|
|
WO2005112919A2
(en)
|
2004-05-19 |
2005-12-01 |
Medarex, Inc. |
Self-immolative linkers and drug conjugates
|
|
AU2004224925C1
(en)
|
2004-08-30 |
2011-07-21 |
Biotest Ag |
Immunoconjugates targeting syndecan-1 expressing cells and use thereof
|
|
AR052774A1
(es)
|
2004-10-08 |
2007-04-04 |
Wyeth Corp |
Inmunoterapia para trastornos autoinmunes
|
|
WO2006065533A2
(en)
|
2004-11-29 |
2006-06-22 |
Seattle Genetics, Inc. |
Engineered antibodies and immunoconjugates
|
|
CA2591148A1
(en)
|
2004-12-09 |
2006-06-15 |
Centocor, Inc. |
Anti-integrin immunoconjugates, methods and uses
|
|
US7408030B2
(en)
|
2005-01-13 |
2008-08-05 |
North Carolina State University |
Purification of immunoglobulins using affinity chromatography and peptide ligands
|
|
US20110166319A1
(en)
|
2005-02-11 |
2011-07-07 |
Immunogen, Inc. |
Process for preparing purified drug conjugates
|
|
ES2503719T3
(es)
*
|
2005-02-11 |
2014-10-07 |
Immunogen, Inc. |
Procedimiento para preparar conjugados de anticuerpos y de maitansinoides
|
|
EP1869084A2
(en)
|
2005-03-04 |
2007-12-26 |
Biogen Idec MA Inc. |
Methods of humanizing immunoglobulin variable regions through rational modification of complementarity determining residues
|
|
US20060233814A1
(en)
|
2005-04-15 |
2006-10-19 |
Immunogen Inc. |
Elimination of heterogeneous or mixed cell population in tumors
|
|
GB2427360A
(en)
|
2005-06-22 |
2006-12-27 |
Complex Biosystems Gmbh |
Aliphatic prodrug linker
|
|
PL2233156T3
(pl)
*
|
2005-07-15 |
2013-09-30 |
Angiochem Inc |
Zastosowanie polipeptydów aprotyninowych jako nośników w koniugatach farmaceutycznych
|
|
JP2009503105A
(ja)
|
2005-08-03 |
2009-01-29 |
イミュノジェン・インコーポレーテッド |
免疫複合体製剤
|
|
AU2006283726C1
(en)
|
2005-08-24 |
2015-05-07 |
Immunogen, Inc. |
Process for preparing maytansinoid antibody conjugates
|
|
EP1926498A2
(en)
|
2005-09-22 |
2008-06-04 |
Hadasit Medical Research Services And Development Company Ltd. |
Dextran and arabinogalactan conjugates of therapeutically active compounds
|
|
EP1940470B1
(en)
|
2005-09-26 |
2013-04-17 |
Medarex, Inc. |
Antibody-drug conjugates and their use
|
|
EP2298308B1
(en)
|
2005-11-14 |
2013-01-16 |
University Of Southern California |
Integrin-binding small molecules
|
|
US7964415B2
(en)
|
2006-04-26 |
2011-06-21 |
Cardiogenics Inc. |
Stable water-soluble polyethylenimine conjugates and methods of use thereof
|
|
CL2007001536A1
(es)
|
2006-05-30 |
2008-01-25 |
Genentech Inc |
Anticuerpos anti-cd22; polinucleotidos que los codifica; vector y celula huesped que los comprende; metodo de fabricacion; metodo de deteccion del anticuerpo en una muestra biologica; inmunoconjugado que comprende al anticuerpo; composicion que lo comprende y su uso para tratar trastornos proliferativos de celulas b.
|
|
NZ574215A
(en)
*
|
2006-07-18 |
2012-07-27 |
Sanofi Aventis |
Antagonist antibody against epha2 for the treatment of cancer
|
|
US20080213349A1
(en)
|
2006-09-11 |
2008-09-04 |
Deepak Ramesh Thakker |
Liposome Complexes Containing Pharmaceutical Agents and Methods
|
|
US20100075375A1
(en)
|
2006-10-03 |
2010-03-25 |
Novo Nordisk A/S |
Methods for the purification of polypeptide conjugates
|
|
EP1914242A1
(en)
|
2006-10-19 |
2008-04-23 |
Sanofi-Aventis |
Novel anti-CD38 antibodies for the treatment of cancer
|
|
SI2019104T1
(sl)
|
2007-07-19 |
2013-12-31 |
Sanofi |
Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
|
|
HUE034763T2
(en)
|
2008-04-30 |
2018-02-28 |
Immunogen Inc |
Crosslinkers and their use
|
|
CN102083461B
(zh)
|
2008-04-30 |
2014-09-17 |
伊缪诺金公司 |
有效的偶联物和亲水性连接体
|
|
GB0811743D0
(en)
|
2008-06-26 |
2008-07-30 |
Hemosol Biopharma Inc |
Composition
|
|
EP2355799A4
(en)
|
2008-11-17 |
2012-09-05 |
Enzon Pharmaceuticals Inc |
CLEANABLE FUSOGENIC LIPIDS FOR NUCLEIC ACID RELIEF SYSTEMS
|
|
SG173152A1
(en)
|
2009-02-05 |
2011-08-29 |
Immunogen Inc |
Novel benzodiazepine derivatives
|
|
UY32560A
(es)
|
2009-04-29 |
2010-11-30 |
Bayer Schering Pharma Ag |
Inmunoconjugados de antimesotelina y usos de los mismos
|
|
MX2011012794A
(es)
|
2009-06-03 |
2012-05-08 |
Immunogen Inc |
Metodos de conjugacion.
|
|
FR2947269B1
(fr)
|
2009-06-29 |
2013-01-18 |
Sanofi Aventis |
Nouveaux composes anticancereux
|
|
UY32914A
(es)
*
|
2009-10-02 |
2011-04-29 |
Sanofi Aventis |
Anticuerpos que se usan específicamente al receptor epha2
|
|
TW201117814A
(en)
|
2009-10-02 |
2011-06-01 |
Sanofi Aventis |
New maytansinoids and the use of said maytansinoids to prepare conjugates with an antibody
|
|
TWI672318B
(zh)
|
2010-02-24 |
2019-09-21 |
美商免疫遺傳股份有限公司 |
葉酸受體１抗體類和免疫共軛物類及彼等之用途
|
|
SMT201900549T1
(it)
|
2010-03-12 |
2019-11-13 |
Debiopharm Int Sa |
Molecole leganti il cd37 e loro immunoconiugati
|
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
|
AU2011320318B9
(en)
|
2010-10-29 |
2015-11-19 |
Immunogen, Inc. |
Non-antagonistic EGFR-binding molecules and immunoconjugates thereof
|
|
US8790649B2
(en)
|
2010-10-29 |
2014-07-29 |
Immunogen, Inc. |
EGFR-binding molecules and immunoconjugates thereof
|
|
US20120149732A1
(en)
|
2010-12-14 |
2012-06-14 |
Alexander Chucholowski |
Multifunctional linkers and methods for the use thereof
|
|
KR20190089048A
(ko)
|
2011-02-15 |
2019-07-29 |
이뮤노젠 아이엔씨 |
컨쥬게이트의 제조방법
|
|
BR112013025228A2
(pt)
|
2011-03-29 |
2018-09-25 |
Immunogen Inc |
processo para fabricar conjugados de homogeneidade aperfeçoada
|
|
ME03353B
(me)
|
2011-03-29 |
2019-10-20 |
Immunogen Inc |
Priprema konjugata antitela i majtanzinoida jednostepenim postupkom
|
|
WO2012135517A2
(en)
*
|
2011-03-29 |
2012-10-04 |
Immunogen, Inc. |
Preparation of maytansinoid antibody conjugates by a one-step process
|
|
CN114441757A
(zh)
|
2011-04-01 |
2022-05-06 |
伊缪诺金公司 |
用于增加folr1癌症治疗的功效的方法
|
|
US20130071482A1
(en)
|
2011-09-20 |
2013-03-21 |
The University Of Kentucky Research Foundation |
Block copolymer cross-linked nanoassemblies as modular delivery vehicles
|
|
WO2013090590A1
(en)
|
2011-12-13 |
2013-06-20 |
Immunogen, Inc. |
Use of n-hydroxysuccinimide to improve conjugate stability
|
|
WO2014055877A1
(en)
|
2012-10-04 |
2014-04-10 |
Immunogen, Inc. |
Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
|
|
HK1213148A1
(zh)
|
2012-10-04 |
2016-06-30 |
Immunogen, Inc. |
離子交換膜的從細胞結合劑細胞毒性劑綴合物中去除雜質的用途
|
|
US20150306242A1
(en)
|
2012-10-04 |
2015-10-29 |
Immunogen, Inc. |
Process for preparing stable antibody maytansinoid conjugates
|
|
US10253099B2
(en)
|
2012-12-05 |
2019-04-09 |
Ruprecht-Karls-Universität Heidelberg |
Conjugates of proteins and multivalent cell-penetrating peptides and their uses
|